Jin Xin Reproductive (01951) announced that through continuous optimization of operational measures, its in-vitro fertilization (IVF) egg retrieval cycle numbers saw further improvement in the fourth quarter of 2025 compared to the third quarter. Although performance in the first half of 2025 declined by 8.0% compared to the same period in 2024, the Group's Greater China business demonstrated strong resilience for the full year 2025, with annual performance decreasing by a marginal 0.4% and essentially returning to 2024 levels. For the year ended December 31, 2025, the overall decline in the Group's IVF egg retrieval cycles narrowed from -5.2% (comparing the first three quarters of 2024 to the first three quarters of 2025) to -1.4% (comparing the full year 2024 to the full year 2025). Notably, the Group's flagship hospital in Chengdu showed marked improvement, with its IVF egg retrieval cycles shifting from a decline of -1.9% in the first three quarters of 2025 to a year-on-year growth of 1.3% for the full year. Concurrently, the decline in IVF egg retrieval cycles in the Greater Bay Area narrowed from -13.5% in the first three quarters of 2025 to -5.9% for the full year. The Group's overseas markets, including the United States and Laos, also saw their IVF egg retrieval cycle decline narrow from -10.8% in the first three quarters of 2025 to -6.9% for the full year. Looking ahead to 2026 and beyond, the Group will persistently enhance clinical treatment outcomes, patient care quality, and service delivery, accelerate the iterative upgrade of core reproductive medical technologies, and deepen scientific research innovation and clinical translation in reproductive medicine. It will also optimize medical processes and digital service experiences, further consolidate the regional market position of its Chengdu flagship hospital, and expedite capacity release and market expansion following the relocation of new facilities in the Greater Bay Area. Simultaneously, the Group will proactively adapt to overseas policy changes and explore growth potential in international markets. Leveraging the benefits of national fertility support policies and industry development opportunities, the company will continue to strengthen its competitiveness to provide superior medical services for patients, ultimately aiming to create long-term, stable value returns for shareholders and contribute to the high-quality development of the industry.